Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.
Dankner M, Rousselle E, Petrecca S, Fabi F, Nowakowski A, Lazaratos AM, Rajadurai CV, Stein AJB, Bian D, Tai P, Belaiche A, Li M, Quaiattini A, Normanno N, Arcila M, Elkrief A, Johnson DB, Ladanyi M, Rose AAN.
Dankner M, et al. Among authors: johnson db.
JCO Precis Oncol. 2025 Jan;9:e2400199. doi: 10.1200/PO.24.00199. Epub 2025 Jan 27.
JCO Precis Oncol. 2025.
PMID: 39869838
Review.